Evidence map›Paper›PMID 38507431›Full record

ArticlePloS one2024

Association between smoking and lack of HIV virological suppression in a cross-sectional study of persons with HIV on antiretroviral therapy in Uganda.

Adah Tumwegamire, Robin Fatch, Nneka I Emenyonu, Sara Lodi, Winnie R Muyindike, Allen Kekibiina, Julian Adong, Christine Ngabirano, Brian Beesiga, Kara Marson and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Adah TumwegamireGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0009-0006-7224-9106
Robin FatchDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, United States of America.
Nneka I EmenyonuDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, United States of America.
Sara LodiBoston University School of Public Health, Boston, Massachusetts, United States of America.
Winnie R MuyindikeGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0002-6694-2645
Allen KekibiinaGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.
Julian AdongGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.
Christine NgabiranoGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0003-0348-316X
Brian BeesigaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0001-5927-8857
Kara MarsonDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, United States of America.
Nakisa GolabiDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, United States of America.
Moses KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Gabriel ChamieDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, United States of America.
Judith A HahnDivision of HIV, Infectious Disease and Global Medicine, University of California San Francisco, San Francisco, United States of America.ORCID 0000-0002-2697-8264
University of California, San Francisco · USMbarara University of Science and Technology · UGInfectious Diseases Research Collaboration · UGBoston University · US

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
URBAN ARCH (3/5) Uganda Cohort TB preventive therapy for HIV-infected alcohol users in Uganda: an evaluation of safety tolerability and adherenceU01AA020776 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2011 to 2021
$4.7M
Interventions to reduce alcohol use and increase adherence to TB preventive therapy among HIV/TB co-infected drinkers (DIPT 1/2)U01AA026223 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2017 to 2021
$2.8M
Interventions to reduce alcohol use and increase adherence to TB preventive therapy among HIV/TB co-infected drinkers (DIPT 2/2)U01AA026221 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAMIE, GABRIEL · 2017 to 2021
$2.7M
Training in Research Program on Alcohol Use by Persons with our at Risk for HIVK24AA022586 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2013 to 2023
$1.8M
NIAAA NIH HHS K24 AA022586NIAAA NIH HHS U01 AA020776NIAAA NIH HHS U01 AA026221NIAAA NIH HHS U01 AA026223NIAID NIH HHS P30 AI042853
6 · The paper itself

Abstract

backgroundSmoking and alcohol use frequently co-occur and are the leading causes of preventable death in sub-Saharan Africa (SSA) and are common among people living with HIV (PLWH). While alcohol use has been shown to be associated with reduced adherence to antiretroviral treatment (ART), which may affect HIV viral suppression, the independent effect of smoking on HIV outcomes in SSA is unknown. We aimed to 1) describe the prevalence of current smoking and correlates of smoking; 2) assess the association of smoking with viral suppression, adjusting for level of alcohol use; 3) explore the relationship between smoking and CD4 cell count <350 cells/mm3, among participants who are virally suppressed.

methodsWe analyzed data from the Drinkers Intervention to Prevent Tuberculosis (DIPT) and the Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) studies conducted in Southwest Uganda. The studies enrolled PLWH who were on ART for at least 6 months and co-infected with latent tuberculosis and dominated with participants who had unhealthy alcohol use. Current smoking (prior 3 months) was assessed by self-report. Alcohol use was assessed using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C, modified for prior 3 months) and phosphatidylethanol (PEth), an alcohol biomarker. We used logistic regression to estimate the cross-sectional association between smoking and lack of virological suppression (≥40 copies/ml), adjusting for level of alcohol use and other covariates, and to examine the association between smoking and CD4 cell counts among PLWH with viral suppression.

resultsOf the 955 participants enrolled from 2017 to 2021 who had viral load (VL) results, 63% were men, median age was 40 years (interquartile range [IQR] 32-47), 63% engaged in high/very high-risk alcohol use (AUDIT-C≥6 or PEth≥200 ng/mL), and 22% reported smoking in the prior 3 months. Among 865 participants (91%) with viral suppression and available CD4 count, 11% had a CD4 cell count <350 cells/mm3. In unadjusted and adjusted analyses, there was no evidence of an association between smoking and lack of virological suppression nor between smoking and CD4 count among those with viral suppression.

conclusionsThe prevalence of smoking was high among a study sample of PLWH in HIV care with latent TB in Southwest Uganda in which the majority of persons engaged in alcohol use. Although there was no evidence of an association between smoking and lack of virological suppression, the co-occurrence of smoking among PLWH who use alcohol underscores the need for targeted and integrated approaches to reduce their co-existence and improve health.

Indexed as

AlcoholismAnti-HIV AgentsHIV InfectionsAdultAnti-Retroviral AgentsCD4 Lymphocyte CountCross-Sectional StudiesEthanolFemaleHumansMaleSmokingUgandaViral LoadAnti-HIV AgentsAnti-Retroviral AgentsEthanol

Identifiers

PMID38507431
PMCPMC10954112
OpenAlexW4392983726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.